{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:30:14Z","timestamp":1726471814021},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.diagmicrobio.2015.05.002","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T21:16:03Z","timestamp":1430946963000},"page":"46-48","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CYP2C19*17 genetic polymorphism\u2014an uncommon cause of voriconazole treatment failure"],"prefix":"10.1016","volume":"83","author":[{"given":"Maheen Z.","family":"Abidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krutika","family":"Kuppalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Ledeboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parmeswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0015","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-006-0025-x","article-title":"Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients","volume":"162","author":"Bhatti","year":"2006","journal-title":"Mycopathologia"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","article-title":"Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring","volume":"33","author":"Hassan","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5414\/CP202014","article-title":"Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections","volume":"52","author":"Kim","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/524670","article-title":"What is the \u201ctherapeutic range\u201d for voriconazole?","volume":"46","author":"Lewis","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0010","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0035","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/pgs.11.18","article-title":"Pharmacogenomics of the triazole antifungal agent voriconazole","volume":"12","author":"Mikus","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.00957-06","article-title":"Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods","volume":"51","author":"Pascual","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/2047-783X-16-4-139","article-title":"Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis: review of the literature","volume":"16","author":"Sandherr","year":"2011","journal-title":"Eur J Med Res"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis","volume":"11","author":"Seyedmousavi","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0080","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1445-5994.2011.02454.x","article-title":"Voriconazole toxicity related to polymorphisms in CYP2C19","volume":"41","author":"Suan","year":"2011","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0100","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2015.05.002_bb0110","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T16:59:52Z","timestamp":1537635592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889315001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0732889315001522"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.05.002","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C19*17 genetic polymorphism\u2014an uncommon cause of voriconazole treatment failure","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}